EUVIMEDEUVIMED entdecken
Fallbericht

High-level multi-class transmitted antiretroviral resistance in a man with newly acquired HIV

Theodore R Miller iD, Cristina Gruta, Raymund Sison, Daniel S Fierer

International Journal of STD & AIDS · 2026

DOI: 10.1177/09564624251396374 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of STD & AIDS, 2026. Verfasst von Theodore R Miller und 3 weiteren Autor:innen. Beteiligte Einrichtung: Apicha Health Center, New York, NY, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Anti-HIV Agents, Drug Resistance, Multiple, Viral. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 19 year old man was diagnosed newly acquired HIV and prescribed bictegravir/emtricitabine/tenofovir alafenamide at his initial visit for HIV care. The genotype results from that initial visit returned two weeks later, showing high-level multi-class transmitted drug resistance, including multiple resistance-associated mutations (RAM) in the integrase gene. Although he had an initial substantial decline in viremia in the first 4 weeks, it was felt that the risk of subsequent failure was too high, and his antiretroviral treatment (ART) regimen was therefore changed to daily dolutegravir and darunavir/cobicistat/emtricitabine/tenofovir alafenamide, plus injected lenacapavir. He had durable virologic suppression on this new regimen for 12 months as of his last follow-up. This case of high-level multi-class transmitted drug resistance, in the context of rapid emergence of resistance to dolutegravir where it has been used as part of a salvage regimen, suggests that assessing for RAM in the integrase gene should be added to the currently recommended resistance testing for all patients with newly acquired HIV prior to initiating ART.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Anti-HIV AgentsDrug Resistance, Multiple, ViralDrug Resistance, ViralHumansMaleHeterocyclic Compounds, 3-RingPyridonesPiperazinesYoung AdultTenofovirEmtricitabineOxazinesViral LoadTreatment OutcomeMutationDarunavir

Stichwörter der Autor:innen

antiretroviral therapy (ART)genotypic resistancemulti-class resistanceresistance-associated mutations (RAM)transmitted drug resistance (TDR)

Substanzen

Heterocyclic Compounds, 3-RingPyridonesPiperazinesAnti-HIV AgentsTenofovirEmtricitabineOxazinesDarunavir

Autor:innen und Institutionen

  • Apicha Health Center, New York, NY, USA.
  • National Clinician Consultation Center, Department of Family and Community Medicine, UCSF, San Francisco, CA, USA.
  • Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Theodore R Miller

Zitieren

APA

Miller, T. R., Gruta, C., Sison, R., & Fierer, D. S. (2026). High-level multi-class transmitted antiretroviral resistance in a man with newly acquired HIV. International Journal of STD & AIDS. https://doi.org/10.1177/09564624251396374

Vancouver

Miller TR, Gruta C, Sison R, Fierer DS. High-level multi-class transmitted antiretroviral resistance in a man with newly acquired HIV. International Journal of STD & AIDS. 2026. doi:10.1177/09564624251396374

BibTeX
@article{Miller2026,
  author = {Miller, Theodore R and Gruta, Cristina and Sison, Raymund and Fierer, Daniel S},
  title = {High-level multi-class transmitted antiretroviral resistance in a man with newly acquired HIV},
  journal = {International Journal of STD & AIDS},
  year = {2026},
  doi = {10.1177/09564624251396374}
}
Kostenlos starten →